Wanbury Q4 FY26 results: Revenue Rs 650 Cr, PAT jumps 117% YoY

Mgmt Guided Margin ImprovementCfo Debt Reduction RoadmapOrder Pipeline DisclosedInvestor Communications View source PDF

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.1%1-day move

₹288.15

prior close

₹288.45

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.0-0.8—-0.0-1.1-1.2-2.9-5.8-1.1+3.8+14.2———

Up moveDown movePending

AI summary

Wanbury's FY26 revenue grew 8% to Rs 650 Cr with EBITDA up 35% to Rs 108 Cr (highest ever). Margins expanded 323 BPS to 16.6%. PAT jumped 117% to Rs 66 Cr. Q4 revenue fell 4% YoY due to West Asia crisis affecting API exports. Debt cut 75% from peak of Rs 700 Cr; cost of borrowing down from 22.5% to 12.5%. API is 88% of revenue. Launched new anaesthetic API in Q4 and plans 4 new molecules yearly from FY27. Formulations hit break-even.

Likely market impact

Strong FY26 with record EBITDA, margin expansion and major debt reduction signals a turnaround story. Q4 export dip is a watch item.